Zimbabwe has rejected a significant American health deal worth $367m (272 million pounds) spanning five years over the United States' request for confidential data.
The decision was revealed after a government memo from December was leaked, which showed President Emmerson Mnangagwa felt the deal was "skewed".
A government spokesperson later stated that the United States was requesting genetic material for research and commercial purposes while was unwilling to guarantee the benefits from any future vaccines.
"We are forced to start the difficult and regrettable process of winding down our support in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy indicated the United States had donated more than $1.9bn for health programmes to Zimbabwe over the last two decades.
A medical body in Zimbabwe has appealed for further talks to reach a agreement suitable to both sides so the country's vital HIV programme can proceed.
Wider Context
This rejection follows a similar situation in neighbouring Kenya, where a high court suspended a related deal with the US after legal challenges were raised about the security of Kenyans' medical information.
Since returning to the presidency recently, US President Donald Trump has slashed foreign aid and shut down the US Agency for International Development (USAID).
The agency had managed assistance for the American government, but Trump claimed its expenditure was "wasteful" and his government was pursuing direct bilateral deals to enhance transparency and accountability.
According to reports, Sixteen nations in Africa have to date signed similar agreements, representing more than $18.3bn in new funding.
Specifics of the Declined Agreement
The funds for Zimbabwe would have supported "HIV/Aids treatment and prevention, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this cooperation would have delivered immense benefits for the people of Zimbabwe, especially the 1.2 million currently on HIV treatment through American-funded programmes," the Ambassador added.
However, government spokesperson Nick Mangwana said the arrangement was "unequal".
"Zimbabwe was being asked to provide its biological resources and data over an extended period, with no corresponding promise of access to any medical innovations – like new medicines or tests – that could result from that shared data," his statement read.
"Effectively, our country would provide the basic resources for scientific discovery without any assurance that the final treatments would be available to our citizens if a new health crisis emerge."
Sovereignty and Global Health
He also noted that the US's withdrawal from the World Health Organization (WHO) and its pursuit of one-on-one deals were undermining frameworks already set up via the international health agency.
The spokesperson cited its Pathogen Access and Benefit Sharing framework created to manage potential pandemics.
"This system is intended to guarantee that when a country provides its information, the benefits – such as vaccines and treatments – are distributed fairly, not commercialised exclusively by those with the resources to develop them."
These objections over the US deal "should not be misconstrued as opposition to America," Mangwana stressed.
"We are open to ongoing dialogue with our American counterparts on how subsequent co-operation might be designed in a manner that honours the sovereignty and interests of both nations."
Medical Community Reaction
A leading public health body said it understood the government's concerns, but urged that talks must proceed considering much of the country's Aids initiatives depended on foreign aid.
"Where technical issues exist, including those involving information security or implementation frameworks, these can frequently be addressed via technical clarification and negotiated safeguards," it said.
The halted deal emphasises the complex challenges between accepting crucial foreign assistance and protecting local interests in an ever more interconnected world.